Faculty
Lindsey A. George, M.D.
Assistant Professor of Pediatrics (Hematology)
Department: Pediatrics
Graduate Group Affiliations
Contact information
Children's Hospital of Philadelphia
3501 Civic Center Blvd
Philadelphia, PA 19104
3501 Civic Center Blvd
Philadelphia, PA 19104
Publications
Education:
BS (Biology)
Cornell University, 2004.
MD
State University at Buffalo School of Medicine and Biological Sciences, 2008.
MSTR (Translational Research)
University of Pennsylvania School of Medicine, 2021.
BS (Biology)
Cornell University, 2004.
MD
State University at Buffalo School of Medicine and Biological Sciences, 2008.
MSTR (Translational Research)
University of Pennsylvania School of Medicine, 2021.
Links
Search PubMed for articles
Perelman School of Medicine at the University of Pennsylvania website
Permanent linkSearch PubMed for articles
Perelman School of Medicine at the University of Pennsylvania website
Description of Clinical Expertise
Coagulation disorders and gene therapy for monogenic disordersDescription of Research Expertise
Dr. Lindsey George is an Assistant Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania and Director of Clinical In Vivo Gene Therapy and Attending Hematologist at the Children’s Hospital of Philadelphia. Her laboratory studies the molecular basis of coagulation with a focus on mechanisms that regulate factor VIII/VIIIa cofactor function to improve understanding of associated disease states of deficiency (hemophilia A) or excess function (thrombosis). Ongoing studies in her group aim to exploit their biochemical insights of FVIII function to develop novel gene-based therapies for hemophilia A. Dr. George has led early-phase, adeno-associated virus (AAV) mediated gene transfer trials for hemophilia A and B. Her Clinical In Vivo Gene Therapy group conducts and supports translational and clinical research in in vivo gene addition and editing as well as aims to implement licensed AAV vectors safely and efficiently across the institution. Dr. George is a member of the Board of Directors of the American Society of Gene and Cell Therapy and participates in multiple national and international professional societies for hemostasis and gene therapy research.Selected Publications
Morris JJ, Parsons NA, Wilhelm AR, Davidson RJ, Olenick LK, Watson CT, Vanden Heuvel A, George LA: Factor IXa and Factor X Influence Factor VIIIa Stability and Inactivation Mechanisms In Vitro and In Vivo. Blood 146(18): 2259-2271, Sep 2025 Notes: Published with an accompanying editorial.Keselman DJ, Small JC, Seneviratne T, McCague S, Kaschak TL, Yum SW, O'Brien A, Brandsema JF, Diamond T, Loomes KM, Lin KY, Wittlieb-Weber CA, Mayer OH, Daniel SG, Waldman AT, Samelson-Jones BJ, Matesanz SE, George LA: Real-World Outcomes of Delandistrogene Moxeparvovec Gene Therapy: Motor Outcomes and Emerging Safety Concerns. Mol Ther Page: doi: 10.1016, Oct 2025 Notes: Published with an accompanying editorial.
Byrne BJ, Flanigan KM, Matesanz SE, Finkel RS, Waldrop MA, D'Ambrosio ES, Johnson NE, Smith BK, Bönnemann C, Carrig S, Rossano JW, Greenberg B, Lalaguna L, Lara-Pezzi E, Subramony S, Corti M, Mercado-Rodriguez C, Leon-Astudillo C, Ahrens-Nicklas R, Bharucha-Goebel D, Gao G, Gessler DJ, Hwu WL, Chien YH, Lee NC, Boye SL, Boye SE, George LA: Current clinical applications of AAV-mediated gene therapy. Mol Ther 33(6): 2479-2516, Jun 2025.
Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC: Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med 392(22): 2235-2243, Jun 2025.
Doshi BS, Markmann CA, Novak N, Rojas SJ, Davidson R, Chau JQ, Wang W, Carrig S, Rus CM, Samelson-Jones BJ, Small JC, Bhoj VG, George LA: Use of CD19-targeted Immune Modulation to Eradicate AAV Neutralizing Antibodies. Mol Ther 8(1): 177-7, Mar 2025 Notes: Published with an accompanying editorial.
Sternberg AR, Martos-Rus C, Davidson RJ, Liu X, George LA.: Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice. Nat Commun 15(1): 7193, Aug 2024.
Samelson-Jones BJ, Doshi BS, George LA: Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies. Blood 144(21): 2185-2197, Nov 2024.
George LA, Monahan PE, Eyster ME, Sullivan SK, Ragni MV, Croteau SE, Rasko JEJ, Recht M, Samelson-Jones BJ, MacDougall A, Jaworski K, Noble R, Curran M, Kuranda K, Mingozzi F, Chang T, Reape KZ, Anguela XM, High KA: Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med 385(21): 1961-1973, Nov 2021 Notes: Corresponding author.
Wilhelm AR, Parsons NA, Samelson-Jones BJ, Davidson RJ, Esmon CT, Camire RM, George LA: Activated protein C has a regulatory role in factor VIII function. Blood 137(18): 2532-2543, May 2021.
George LA, Sullivan SK, Giermasz G, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majuddar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hu Di, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA : Hemophilia B Gene Therapy with a High Specific Activity Factor IX Variant N Engl J Med 377(2): 2215-2227, Dec 2017 Notes: Corresponding author, published with accompanying editorial.
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.